Kymera Therapeutics (NASDAQ: KYMR) reported Q4 EPS of ($0.60), $0.03 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $16.1 million versus the consensus estimate of $22.09 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.